PMID: 8632538Apr 1, 1996

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up

The Journal of Urology
David A TolleyP Whelan


We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer. A multicenter randomized clinical trial was done involving 502 patients with newly diagnosed superficial bladder cancer. After complete transurethral resection patients with newly diagnosed superficial bladder cancer. After complete resection patients were randomized into 1 of 3 treatment arms: no further treatment, 1 instillation of mitomycin C at resection and 1 instillation at resection and at 3-month intervals for 1 year (total 5 instillations). The dose of mitomycin C used was 40 mg./40 ml. water. End points were interval to first superficial recurrence, recurrence rate (defined as the number of positive cystoscopies per year) and progression-free interval rate (progression defined as the development of muscle invasive or metastatic disease, or death from bladder cancer). After median followup of 7 years 1 and 5 instillations of mitomycin C resulted in decreased recurrence rates and increased recurrence-free interval. The benefit of mitomycin C was observed in patients at low, medium and high risk for subsequent recurrence. There was suggestive but not conclusive evidence that...Continue Reading


Jun 1, 1978·British Journal of Urology·B H PageM P Curwen
Apr 11, 1992·Lancet·L C Barr, M Baum
Jan 1, 1992·The Prostate. Supplement·F H SchröderMichele Pavone-Macaluso
Jun 1, 1990·Statistics in Medicine·S J Pocock, M D Hughes
Jan 1, 1990·Journal of Clinical Epidemiology·S G Thompson, S J Pocock
Nov 30, 1974·Lancet·P J Boyd, K G Burnand
Jan 1, 1980·Scandinavian Journal of Urology and Nephrology·S FianuV Václavinková
Dec 24, 1994·BMJ : British Medical Journal·C E CounsellP A Sandercock


Dec 2, 1998·International Journal of Cancer. Journal International Du Cancer·K N SyrigosA A Epenetos
Nov 27, 2004·Cancer Immunology, Immunotherapy : CII·Ellen A M Schenk-Braat, Chris H Bangma
Nov 12, 2010·Cancer Chemotherapy and Pharmacology·Antonia TsallasHelen Burt
Oct 19, 2006·World Journal of Urology·Dragan J GolijaninSeth P Lerner
Mar 10, 2009·World Journal of Urology·K D SievertArnulf Stenzl
May 12, 2007·Wiener medizinische Wochenschrift·Daniel MeyerDaniel S Engeler
May 5, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Milène VolpatoRoger M Phillips
May 5, 2005·Urologic Oncology·Douglas W SoderdahlD H Bagley
Jun 21, 2002·European Urology·Willem OosterlinckEuropean Association of Urology (EAU) Working Group on Oncological Urology
Dec 13, 2002·European Urology·Dominique K Chopin, Bernard Gattegno
Aug 6, 2003·Critical Reviews in Oncology/hematology·Per-Uno Malmström
Jul 1, 1998·Urologic Oncology·H B GrossmanT L Ratliff
May 8, 2007·Nature Clinical Practice. Urology·Guido Dalbagni
Sep 25, 2012·Journal of Endourology·Agnes J WangMichael N Ferrandino
Apr 20, 2001·Journal of the National Cancer Institute·James E Montie
Jun 5, 2003·Current Opinion in Oncology·Lester S BordenM Craig Hall
Mar 25, 2006·Journal of Clinical Pathology·Alan G SpeersAlan J Cooper
Jun 12, 2004·Postgraduate Medical Journal·T R Leyshon Griffiths, J Kilian Mellon
May 31, 2012·Advances in Urology·Daniel A BarocasRachel J Spear
Jun 6, 2014·BioMed Research International·Francesco MistrettaMassimo Lazzeri
Jun 23, 2006·Der Urologe. Ausg. A·Peter J GoebellH Rübben
Oct 17, 2014·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Teng LiMin Chen
Oct 1, 2008·Journal of Cancer Research and Clinical Oncology·Yigang QianShusen Zheng
Apr 13, 2007·Expert Review of Anticancer Therapy·David JosephsonJohn P Stein
Aug 24, 2006·Expert Review of Anticancer Therapy·Adam R Metwalli, Ashish M Kamat
Oct 6, 2006·Expert Review of Anticancer Therapy·Ingo KauschD Jocham
Feb 16, 2005·Expert Opinion on Biological Therapy·Anthony J GlackinKate E Williamson
Jul 9, 2008·Cancer Investigation·Yigang QianShusen Zheng
Jun 13, 2009·Lancet·Donald S KaufmanAdam S Feldman
Sep 18, 2007·The Journal of Urology·Alan G SpeersAlan J Cooper
Aug 22, 2003·BJU International·N Thiruchelvam, H Mostafid
Aug 21, 2013·International Journal of Cancer. Journal International Du Cancer·Karen J BowmanGeorge D D Jones
Jul 11, 2003·The Journal of Urology·Marc-Oliver GrimmThomas Alexander Vogeli
Apr 22, 2015·Der Urologe. Ausg. A·T J SchnöllerF Jentzmik
Apr 2, 2013·The Urologic Clinics of North America·David C JohnsonMichael E Woods
Apr 9, 2005·Surgical Oncology Clinics of North America·Federico A Corica, Thomas E Keane
Sep 22, 2009·The Journal of Urology·Narendrakumar BirareAlan J Cooper
Feb 14, 2007·The Journal of Urology·Paramananthan MariappanDavid A Tolley
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Menachem LauferMerrill J Egorin
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido DalbagniDean Bajorin
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renzo ColomboMichele Pavone-Macaluso
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donald Lamm
Jun 22, 2016·European Urology·Marko BabjukRichard Zigeuner
Feb 23, 1999·The Urologic Clinics of North America·M J Young, Mark Soloway
Mar 31, 2004·The Medical Clinics of North America·Michael J Droller
Jan 10, 2006·Urology·Alan M NiederMichael A S Jewett
Jan 10, 2006·Urology·Willem OosterlinckPaul Sved
Jun 3, 2014·Current Opinion in Urology·Matthew Mossanen, John L Gore
May 8, 2018·Expert Opinion on Emerging Drugs·Jasper Crijnen, Theo M De Reijke
Jan 12, 1999·British Journal of Urology·J Murray, D Skennerton
Oct 8, 2016·Urologia·Vincenzo SerrettaGiovanni Caruana
Oct 8, 2016·Urologia·Savino M Di StasiVincenzo Pagliarulo
Apr 15, 2003·The Journal of Pathology·John R W MastersMRC Superficial Bladder Cancer Group Mitomycin-C Trial Collaborators
Oct 26, 2018·Current Urology Reports·Benjamin T Ristau, Marc C Smaldone
Oct 26, 2018·Current Urology Reports·Timo K NykoppPeter Black
Mar 26, 2002·The Journal of Urology·Mark SolowayAnil Vaidya
Oct 20, 2015·The Journal of Urology·Nicholas A WilliamsHrishi B Joshi
Sep 1, 2007·Current Opinion in Urology·Kees Hendricksen, J Alfred Witjes
Nov 28, 2008·BJU International·Seth P Lerner, Jessie L-S Au
Feb 3, 2010·BJU International·Benjamin E AyresAction for Bladder Cancer
Mar 13, 2014·Nature Reviews. Urology·Homayoun ZargarPeter Black
Dec 5, 2008·Scandinavian Journal of Urology and Nephrology. Supplementum·Tadao KakizoeMichael J Droller
Mar 9, 2010·Expert Opinion on Pharmacotherapy·Steve K WilliamsMark Soloway
Jul 23, 2011·Cancer·Karim ChamieUrologic Diseases in America Project
Aug 9, 2011·Cancer·Karim ChamieUrologic Diseases in America Project
Aug 23, 2019·Nature Reviews. Urology·Gregory A JoiceMax Kates
Jun 5, 2010·Annals of the Royal College of Surgeons of England·Richard T BryanGraham M Sole

Related Concepts

Intravesical Injection
Antibiotics, Cytotoxic
Malignant Neoplasm of Urinary Bladder
Carcinoma, Transitional Cell
Combined Modality Therapy
Neoplasm Recurrence, Local
Chemotherapy, Adjuvant
Progression-Free Survival

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.